£495.00

It has never been this cheap. We have no record of a lower price.

£495 today · cheaper than every other day in the last 3 months

2023-2028 Monoclonal Antibodies Outlook for Japan - mAbs Market

View at Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 37 days · 37 data points (no recent data)

Historical
Generating forecast…
£495.00 £470.25 £480.15 £490.05 £499.95 £509.85 £519.75 23 August 2026 01 September 2026 10 September 2026 19 September 2026 28 September 2026
View at Amazon ↗

Price data last checked 54 day(s) ago - refreshing...

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

Price distribution over 37 days • 1 price levels

Days at Price
37 days 0 9 19 28 37 £495 Days at Price

Price Analysis

Most common price: £495 (37 days, 100.0%)

Price range: £495 - £495

Price levels: 1 different prices over 37 days

Description

Gain comprehensive insights into the monoclonal antibodies market across Japan with this detailed 2023-2028 outlook report. The study provides latent demand forecasts measured in millions of U.S. dollars for mAbs across Japanese prefectures and over 1,000 cities, offering potential industry earnings (P.I.E.) estimates for strategic planning. Each city's percentage share relative to its prefecture and Japan as a whole is included, enabling readers to benchmark markets effectively. This econometric analysis covers fundamental market drivers and competitive dynamics, making it an essential resource for distribution managers, sales strategists and pharmaceutical industry professionals seeking data-driven insights into regional mAb demand patterns and growth opportunities throughout Japan.

Key Features

Latent demand forecasts for monoclonal antibodies across Japanese prefectures and over 1,000 cities through 2028.

Potential industry earnings (P.I.E.) estimates provided in millions of U.S. dollars for regional market assessment.

Comparative benchmarking showing each city's percentage share of its prefecture and Japan's total mAbs market.

Econometric models project fundamental demand drivers to support distribution and sales force strategy development.

Published by ICON Group International, Inc., a recognised authority on market analysis and industry forecasting.

Product Specifications

Format
paperback
Domain
Amazon UK
Release Date
28 November 2022
Listed Since
08 December 2022

Similar Products You Might Like

The 2023-2028 Outlook for Monoclonal Antibodies Market in Breast Cancers in India
90% match

The 2023-2028 Outlook for Monoclonal Antibodies Market in Breast Cancers in India

£515.00 27 Sep 2026
2023-2028 Cognitive Memory Enhancer Drugs Outlook Japan
89% match

2023-2028 Cognitive Memory Enhancer Drugs Outlook Japan

£495.00 28 Sep 2026
The 2023-2028 Outlook for Genital Herpes Treatments in Japan
89% match

The 2023-2028 Outlook for Genital Herpes Treatments in Japan

£495.00 24 Oct 2026
2023-2028 Artificial Tears Market Outlook Japan - Cities & Prefectures
89% match

2023-2028 Artificial Tears Market Outlook Japan - Cities & Prefectures

£495.00 28 Sep 2026
The 2023-2028 Outlook for Orphan Biologic Drugs in India
89% match

The 2023-2028 Outlook for Orphan Biologic Drugs in India

£515.00 27 Sep 2026
The 2023-2028 Outlook for Pharmaceuticals for US Zip Codes
89% match

The 2023-2028 Outlook for Pharmaceuticals for US Zip Codes

£490.00 27 Sep 2026
The 2023-2028 Outlook for Allergic Rhinitis in Japan
88% match

The 2023-2028 Outlook for Allergic Rhinitis in Japan

£495.00 15 Sep 2026
The 2023-2028 Outlook for Chronic Disease Management Therapeutics and Device Technologies in the United States
88% match

The 2023-2028 Outlook for Chronic Disease Management Therapeutics and Device Technologies in the United States

£520.00 27 Sep 2026
The 2023-2028 Outlook for Biologic Vasculitis Treatments in the United States
88% match

The 2023-2028 Outlook for Biologic Vasculitis Treatments in the United States

£520.00 27 Sep 2026
The 2023-2028 Outlook for Immune-Oncology Treatments in India
88% match

The 2023-2028 Outlook for Immune-Oncology Treatments in India

£515.00 27 Sep 2026
The 2023-2028 Outlook for GLP-1 Agonists for Type 2 Diabetes in the United States
88% match

The 2023-2028 Outlook for GLP-1 Agonists for Type 2 Diabetes in the United States

£520.00 27 Sep 2026
The 2023-2028 Outlook for Rheumatology Therapeutics in India
88% match

The 2023-2028 Outlook for Rheumatology Therapeutics in India

£515.00 27 Sep 2026
The 2023-2028 Outlook for Hepatitis Drugs in the United States
88% match

The 2023-2028 Outlook for Hepatitis Drugs in the United States

£520.00 27 Sep 2026
The 2023-2028 Outlook for Biologic Vasculitis Treatments in India
88% match

The 2023-2028 Outlook for Biologic Vasculitis Treatments in India

£515.00 27 Sep 2026
The 2023-2028 Outlook for Anti-Viral Nucleotide Polymerase Inhibitor Drugs in the United States
88% match

The 2023-2028 Outlook for Anti-Viral Nucleotide Polymerase Inhibitor Drugs in the United States

£520.00 27 Sep 2026
The 2023-2028 Outlook for Hepatitis Therapeutics in the United States
88% match

The 2023-2028 Outlook for Hepatitis Therapeutics in the United States

£520.00 27 Sep 2026
The 2023-2028 Outlook for Vasculitis Treatments in India
88% match

The 2023-2028 Outlook for Vasculitis Treatments in India

£515.00 27 Sep 2026
The 2023-2028 Outlook for Blood Products in India
87% match

The 2023-2028 Outlook for Blood Products in India

£515.00 27 Sep 2026
The 2023-2028 Outlook for Nucleotide Polymerase Inhibitor Antiviral Drugs in the United States
87% match

The 2023-2028 Outlook for Nucleotide Polymerase Inhibitor Antiviral Drugs in the United States

£520.00 27 Sep 2026
The 2023-2028 Outlook for GLP-1 Agonists for Type 2 Diabetes in India
87% match

The 2023-2028 Outlook for GLP-1 Agonists for Type 2 Diabetes in India

£515.00 27 Sep 2026
The 2023-2028 Outlook for Thyroid Gland Disorders in India
87% match

The 2023-2028 Outlook for Thyroid Gland Disorders in India

£515.00 27 Sep 2026
The 2023-2028 Outlook for Myasthenia Gravis Treatments in India
87% match

The 2023-2028 Outlook for Myasthenia Gravis Treatments in India

£515.00 27 Sep 2026
The 2023-2028 Outlook for Neurology in the United States
87% match

The 2023-2028 Outlook for Neurology in the United States

£520.00 27 Sep 2026
The 2023-2028 Outlook for HIV-AIDS Immunoassay Diagnostics in the United States
87% match

The 2023-2028 Outlook for HIV-AIDS Immunoassay Diagnostics in the United States

£520.00 27 Sep 2026